$CCEL
CRYO CELL INTERNATIONAL INC Stock $ccel

$ccel Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024022275 Filed on February 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$7.852M	$7.877M	$31.34M
YoY Change	0.36%	1.45%	3.32%
Cost Of Revenue	$2.160M	$2.076M	$8.442M
YoY Change	4.5%	-2.96%	-3.98%
Gross Profit	$5.692M	$5.801M	$22.90M
YoY Change	-1.13%	3.13%	6.3%
Gross Profit Margin	72.49%	73.65%	73.07%
Selling, General & Admin	$4.340M	$5.393M	$17.12M
YoY Change	11.88%	15.03%	9.85%
% of Gross Profit	76.24%	92.97%	74.74%
Research & Development	$502.9K	$443.8K	$1.171M
YoY Change	537.91%	480.9%	204.44%
% of Gross Profit	8.84%	7.65%	5.12%
Depreciation & Amortization	$86.05K	$335.9K	$1.400M
YoY Change	-76.74%	-8.99%	-6.62%
% of Gross Profit	1.51%	5.79%	6.11%
Operating Expenses	$4.871M	$5.132M	$18.29M
YoY Change	23.06%	-1.68%	14.54%
Operating Profit	$821.2K	$669.1K	-$12.30M
YoY Change	-51.21%	65.05%	-405.73%
Interest Expense	-$26.78K	$183.1K	$1.237M
YoY Change	-105.74%	-195.88%	-18.73%
% of Operating Profit	-3.26%	27.36%
Other Income/Expense, Net	$60.00	$10.00	-$1.060M
YoY Change	-100.01%	-98.67%	50.31%
Pretax Income	$794.5K	-$15.99M	-$13.36M
YoY Change	-34.58%	-2669.12%	-502.67%
Income Tax	$238.3K	-$4.803M	-$3.843M
% Of Pretax Income	29.99%
Net Earnings	$556.2K	-$11.19M	-$9.522M
YoY Change	-27.46%	-1435.61%	-443.57%
Net Earnings / Revenue	7.08%	-142.06%	-30.38%
Basic Earnings Per Share	$0.07		-$1.14
Diluted Earnings Per Share	$0.07	-$1.35	-$1.14
COMMON SHARES
Basic Shares Outstanding	8.287M	8.287M	8.341M
Diluted Shares Outstanding	8.325M		8.341M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$979.6K	$980.3K	$980.3K
YoY Change	-55.74%	-43.06%	-43.06%
Cash & Equivalents	$247.1K	$406.1K	$406.1K
Short-Term Investments	$732.5K	$574.2K	$574.2K
Other Short-Term Assets	$990.4K	$390.0K	$1.127M
YoY Change	135.21%	-8.65%	13.49%
Inventory	$755.2K	$768.9K	$768.9K
Prepaid Expenses	$535.3K	$615.4K
Receivables	$6.727M	$6.576M	$6.576M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$9.452M	$9.453M	$9.453M
YoY Change	-11.14%	-1.64%	-1.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$22.56M	$21.00M	$22.03M
YoY Change	56.4%	54.35%	55.04%
Goodwill	$1.941M	$1.941M
YoY Change	0.0%	0.0%
Intangibles	$972.2K	$989.1K
YoY Change	-32.45%	-32.41%
Long-Term Investments	$308.0K	$308.0K	$308.0K
YoY Change	0.0%	0.0%	0.0%
Other Assets	$26.47M	$30.77M	$26.50M
YoY Change	-35.54%	-26.16%	-29.06%
Total Long-Term Assets	$52.26M	$51.77M	$51.77M
YoY Change	-5.83%	-6.35%	-6.35%
TOTAL ASSETS
Total Short-Term Assets	$9.452M	$9.453M	$9.453M
Total Long-Term Assets	$52.26M	$51.77M	$51.77M
Total Assets	$61.71M	$61.22M	$61.22M
YoY Change	-6.69%	-5.65%	-5.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.997M	$3.175M	$3.175M
YoY Change	26.78%	97.76%	97.76%
Accrued Expenses	$4.171M	$5.171M	$3.478M
YoY Change	35.64%	44.2%	12.55%
Deferred Revenue	$9.395M	$9.705M
YoY Change	1.53%	1.23%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$168.6K	$165.6K	$165.6K
YoY Change	6.41%	10.04%	10.04%
Total Short-Term Liabilities	$19.37M	$20.86M	$20.86M
YoY Change	2.42%	7.1%	7.1%
LONG-TERM LIABILITIES
Long-Term Debt	$8.392M	$8.430M	$8.430M
YoY Change	-1.83%	-1.75%	-1.75%
Other Long-Term Liabilities	$44.29M	$51.39M	$42.96M
YoY Change	-7.56%	9.5%	12.01%
Total Long-Term Liabilities	$52.68M	$51.39M	$51.39M
YoY Change	9.95%	9.5%	9.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.37M	$20.86M	$20.86M
Total Long-Term Liabilities	$52.68M	$51.39M	$51.39M
Total Liabilities	$72.05M	$72.25M	$72.25M
YoY Change	7.82%	8.79%	8.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$30.60M	-$31.16M
YoY Change	46.63%	44.01%
Common Stock	$43.87M	$43.56M
YoY Change	1.88%	1.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$23.60M	$23.43M
YoY Change	3.17%	3.53%
Treasury Stock Shares
Shareholders Equity	-$10.34M	-$11.03M	-$11.03M
YoY Change
Total Liabilities & Shareholders Equity	$61.71M	$61.22M	$61.22M
YoY Change	-6.69%	-5.65%	-5.65%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$556.2K	-$11.19M	-$9.522M
YoY Change	-27.46%	-1435.61%	-443.57%
Depreciation, Depletion And Amortization	$86.05K	$335.9K	$1.400M
YoY Change	-76.74%	-8.99%	-6.62%
Cash From Operating Activities	-$356.9K	$3.344M	$8.920M
YoY Change	-121.71%	37.64%	4.05%
INVESTING ACTIVITIES
Capital Expenditures	$457.7K	$1.715M	$6.839M
YoY Change	21.86%	-6956.9%	-43.8%
Acquisitions
YoY Change
Other Investing Activities	$116.7K	-$266.7K	-$1.306M
YoY Change	-114.12%	-114.11%	-58.03%
Cash From Investing Activities	-$341.1K	-$1.982M	-$8.145M
YoY Change	-71.62%	-203.45%	-46.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$799.0K
YoY Change			-56.09%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	539.0K	-1.541M	-2.073M
YoY Change	-169.74%	-72.32%	-1501.91%
NET CHANGE
Cash From Operating Activities	-356.9K	3.344M	8.920M
Cash From Investing Activities	-341.1K	-1.982M	-8.145M
Cash From Financing Activities	539.0K	-1.541M	-2.073M
Net Change In Cash	-159.0K	-177.9K	-1.298M
YoY Change	-51.96%	-85.43%	-80.21%
FREE CASH FLOW
Cash From Operating Activities	-$356.9K	$3.344M	$8.920M
Capital Expenditures	$457.7K	$1.715M	$6.839M
Free Cash Flow	-$814.6K	$1.629M	$2.081M
YoY Change	-164.23%	-33.62%	-157.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000862692
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-11-30
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--11-30
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40767
CY2023	dei	Entity Registrant Name EntityRegistrantName	CRYO-CELL INTERNATIONAL, INC.
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-3023093
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	700 Brooker Creek Blvd
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1800
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Oldsmar
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34677
CY2023	dei	City Area Code CityAreaCode	813
CY2023	dei	Local Phone Number LocalPhoneNumber	749-2100
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
CY2023	dei	Trading Symbol TradingSymbol	CCEL
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	27010426
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8286785
CY2023	dei	Auditor Firm AuditorFirmId	344
CY2023	dei	Auditor Name AuditorName	Wipfli LLP
CY2023	dei	Auditor Location AuditorLocation	Atlanta, Georgia
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	406067
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1703958
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	574183
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	17620
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3822300
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3528119
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6576240
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6043941
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	615407
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	566557
CY2023Q4	us-gaap	Inventory Net InventoryNet	768877
CY2022Q4	us-gaap	Inventory Net InventoryNet	851230
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	122113
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	0
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	389950
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	426879
CY2023Q4	us-gaap	Assets Current AssetsCurrent	9452837
CY2022Q4	us-gaap	Assets Current AssetsCurrent	9610185
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20996883
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13603115
CY2023Q4	ccel	Duke License Agreement DukeLicenseAgreement	0
CY2022Q4	ccel	Duke License Agreement DukeLicenseAgreement	13691028
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	989121
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1463312
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	5260119
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	9275344
CY2023Q4	us-gaap	Goodwill Goodwill	1941411
CY2022Q4	us-gaap	Goodwill Goodwill	1941411
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	20492749
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	13742399
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1033157
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	606034
CY2023Q4	ccel	Deposits And Other Assets DepositsAndOtherAssets	746493
CY2022Q4	ccel	Deposits And Other Assets DepositsAndOtherAssets	647226
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	30771050
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	41674754
CY2023Q4	us-gaap	Assets Assets	61220770
CY2022Q4	us-gaap	Assets Assets	64888054
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3174584
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1605301
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5170809
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3585810
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	165641
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	150527
CY2023Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	1222728
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2272728
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	225686
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	297691
CY2023Q4	ccel	Duke License Agreement Liability Current DukeLicenseAgreementLiabilityCurrent	1200000
CY2022Q4	ccel	Duke License Agreement Liability Current DukeLicenseAgreementLiabilityCurrent	1983036
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	9704553
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	9586327
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20864001
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19481420
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	41186800
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	36000059
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	44226
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	1162704
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	8430037
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	8579875
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	851938
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	313298
CY2023Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	875000
CY2022Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	875000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	51388001
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	46930936
CY2023Q4	us-gaap	Liabilities Liabilities	72252002
CY2022Q4	us-gaap	Liabilities Liabilities	66412356
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14849246
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8286785
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14848001
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8500511
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	148492
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	148480
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	43411143
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	42597380
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	23431685
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	22632649
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31159182
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21637513
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-11031232
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1524302
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61220770
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	64888054
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	31343695
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	30336749
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8442310
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8792358
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17115514
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15580274
CY2023	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	3737133
CY2022	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0
CY2023	us-gaap	Impairment Of Ongoing Project ImpairmentOfOngoingProject	13108064
CY2022	us-gaap	Impairment Of Ongoing Project ImpairmentOfOngoingProject	0
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1050978
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	435333
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1171456
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	384789
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1124228
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1119528
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	43647727
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	26312282
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-12304032
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	4024467
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	50777
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-38972
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	122113
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	446200
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	407344
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3441
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1676
CY2023	us-gaap	Interest Expense InterestExpense	1236794
CY2022	us-gaap	Interest Expense InterestExpense	1521767
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1060463
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-705519
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13364495
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3318948
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3842826
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	547540
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-9521669
CY2022	us-gaap	Net Income Loss NetIncomeLoss	2771408
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.14
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.33
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8340839
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8465568
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.14
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.33
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8340839
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8483994
CY2023	us-gaap	Profit Loss ProfitLoss	-9521669
CY2022	us-gaap	Profit Loss ProfitLoss	2771408
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1399667
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1498883
CY2023	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	3737133
CY2022	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0
CY2023	us-gaap	Impairment Of Ongoing Project ImpairmentOfOngoingProject	13108064
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	407344
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1050978
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	435333
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	50777
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-38972
CY2023	ccel	Realized And Unrealized Gain On Interest Rate Swap Contract RealizedAndUnrealizedGainOnInterestRateSwapContract	122113
CY2022	ccel	Realized And Unrealized Gain On Interest Rate Swap Contract RealizedAndUnrealizedGainOnInterestRateSwapContract	0
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	816639
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	461345
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1036390
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	929618
CY2023	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-6750350
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1732266
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	21631
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	15834
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	310744
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	310459
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1568689
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1720386
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	48850
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	8144
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-360445
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-490002
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-36929
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-284329
CY2023	ccel	Increase Decrease In Deposits And Other Assets IncreaseDecreaseInDepositsAndOtherAssets	99267
CY2022	ccel	Increase Decrease In Deposits And Other Assets IncreaseDecreaseInDepositsAndOtherAssets	80756
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	688935
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	115527
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1703958
CY2023	ccel	Lease Liability Arising From Right Of Use Asset LeaseLiabilityArisingFromRightOfUseAsset	737867
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1582135
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	528424
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-271232
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-312067
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	5304967
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	4953476
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8919754
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8572647
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6838969
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12168459
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1870000
CY2023	ccel	Payment Of Duke License Agreement PaymentOfDukeLicenseAgreement	799999
CY2022	ccel	Payment Of Duke License Agreement PaymentOfDukeLicenseAgreement	5000000
CY2023	ccel	Proceeds From Liquidation Of Marketable Securities ProceedsFromLiquidationOfMarketableSecurities	179306
CY2022	ccel	Proceeds From Liquidation Of Marketable Securities ProceedsFromLiquidationOfMarketableSecurities	0
CY2023	ccel	Payments To Acquire Marketable Securities And Other Investments PaymentsToAcquireMarketableSecuritiesAndOtherInvestments	1082923
CY2022	ccel	Payments To Acquire Marketable Securities And Other Investments PaymentsToAcquireMarketableSecuritiesAndOtherInvestments	1142212
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	397831
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1161032
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8144754
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15279639
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	799036
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1819915
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	156355
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1946996
CY2023	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	2000000
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	5400000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	551274
CY2023	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	950000
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	7672728
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	8960000
CY2023	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	0
CY2022	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	7672728
CY2023	ccel	Issuance Costs Associated With The Proceeds From The Note Payable IssuanceCostsAssociatedWithTheProceedsFromTheNotePayable	0
CY2022	ccel	Issuance Costs Associated With The Proceeds From The Note Payable IssuanceCostsAssociatedWithTheProceedsFromTheNotePayable	-196501
CY2023	ccel	Payment Of Earnout PaymentOfEarnout	67500
CY2022	ccel	Payment Of Earnout PaymentOfEarnout	0
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2072891
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	147862
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1297891
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-6559130
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1703958
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8263088
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	406067
CY2022	ccel	Lease Liability Arising From Right Of Use Asset LeaseLiabilityArisingFromRightOfUseAsset	0
CY2023	ccel	Construction Costs Payable ConstructionCostsPayable	880348
CY2022	ccel	Construction Costs Payable ConstructionCostsPayable	0
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1808751
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1259884
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1820802
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1572602
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	4184314
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	551274
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	461345
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1819915
CY2022	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.9
CY2022	us-gaap	Dividends Common Stock DividendsCommonStock	7672728
CY2022	us-gaap	Net Income Loss NetIncomeLoss	2771408
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1524302
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-2864
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	816639
CY2023	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	799036
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-9521669
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-11031232
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Risks</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and cash equivalent accounts in financial institutions, which often exceed the Federal Deposit Insurance Corporation (FDIC) limit. The Company places its cash with high quality financial institutions and believes it is not exposed to any significant credit risk. The Company may from time to time invest some of its cash funds in certificates of deposit and bond investments maintained by brokers who are insured under the Securities Investor Protection Corporation (SIPC). The Company believes these are conservative investments with a low risk for any loss of principal. The Company regularly assesses its marketable security investments for impairment and adjusts its investment strategy as it deems appropriate.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company depends on one supplier for the source of its collection kits</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a critical component of the umbilical cord blood stem cell collection process. However, the Company believes that alternative sources of supply are available.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company depends on three suppliers for the supply and manufacturing of the PrepaCyte CB units. However, the Company believes that alternative sources of supply and manufacturing are available.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company depends on one third party, the National Marrow Donor Program, to manage the public umbilical cord stem cells that are needed for transplant.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During fiscal 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were no concentration of risks.</span></p>
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	535522
CY2023	us-gaap	Concentration Risk Supplier ConcentrationRiskSupplier	The Company depends on one supplier for the source of its collection kits
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">statements </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p>
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	50891353
CY2023Q4	ccel	Revenue Remaining Performance Obligation Next Twelve Months RevenueRemainingPerformanceObligationNextTwelveMonths	9704553
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2005Q4	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	50000
CY2005Q4	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	50000
CY2012Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	75000
CY2017Q2	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	100000
CY2023	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	41056
CY2022	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	50977
CY2023	ccel	Increase Decrease In Capitalized Contract Cost IncreaseDecreaseInCapitalizedContractCost	114139
CY2022	ccel	Increase Decrease In Capitalized Contract Cost IncreaseDecreaseInCapitalizedContractCost	109673
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	695695
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	615628
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6576240
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6043941
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	9704553
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	9586327
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	41186800
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	36000059
CY2023	ccel	Impairment Of Contract Assets ImpairmentOfContractAssets	0
CY2022	ccel	Impairment Of Contract Assets ImpairmentOfContractAssets	0
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	615628
CY2023	ccel	Contract With Customer Asset Net Current Additions ContractWithCustomerAssetNetCurrentAdditions	114139
CY2023	ccel	Contract With Customer Asset Net Current Deductions ContractWithCustomerAssetNetCurrentDeductions	34072
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	695695
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6043941
CY2023	ccel	Accounts Receivable Net Current Additions AccountsReceivableNetCurrentAdditions	34592477
CY2023	ccel	Accounts Receivable Net Current Deductions AccountsReceivableNetCurrentDeductions	34060178
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6576240
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	45586386
CY2023	ccel	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	24738156
CY2023	ccel	Contract With Customer Liability Deductions ContractWithCustomerLiabilityDeductions	19433189
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	50891353
CY2022	ccel	Contract With Customer Asset Net Current Additions ContractWithCustomerAssetNetCurrentAdditions	109673
CY2022	ccel	Contract With Customer Asset Net Current Deductions ContractWithCustomerAssetNetCurrentDeductions	29567
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	615628
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5253173
CY2022	ccel	Accounts Receivable Net Current Additions AccountsReceivableNetCurrentAdditions	38342307
CY2022	ccel	Accounts Receivable Net Current Deductions AccountsReceivableNetCurrentDeductions	37551539
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6043941
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	40632910
CY2022	ccel	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	25069323
CY2022	ccel	Contract With Customer Liability Deductions ContractWithCustomerLiabilityDeductions	20115847
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	45586386
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0
CY2022Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0
CY2023	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	0
CY2022	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	0
CY2023	us-gaap	Advertising Expense AdvertisingExpense	952586
CY2022	us-gaap	Advertising Expense AdvertisingExpense	755921
CY2023	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	51000
CY2022	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-39000
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	122113
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	446200
CY2023	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product Warranty and Cryo-Cell Cares</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Program</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective February 1, 2012, the Company increased the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> payment warranty to a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to all new clients who choose the premium processing method, PrepaCyte CB. The product warranty is available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program, nor has it incurred costs related to these warranties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. In accordance with ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method; therefore, the transaction price does not reflect any expectation of service level credits at November 30, 2023 and November 30, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.</span></p>
CY2005Q4	ccel	Payment Warranty PaymentWarranty	50000
CY2005Q4	ccel	Payment Warranty PaymentWarranty	50000
CY2012Q1	ccel	Increased Payment Warranty IncreasedPaymentWarranty	75000
CY2017Q2	ccel	Increased Payment Warranty IncreasedPaymentWarranty	100000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-9521669
CY2022	us-gaap	Net Income Loss NetIncomeLoss	2771408
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8340839
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8465568
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	18426
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8340839
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8483994
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.14
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.33
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.14
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.33
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	817000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	461000
CY2023Q4	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	3737133
CY2022Q4	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0
CY2023Q4	ccel	Inventory Collection Kits InventoryCollectionKits	47739
CY2022Q4	ccel	Inventory Collection Kits InventoryCollectionKits	41463
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	7718
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	7718
CY2023Q4	ccel	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	6028996
CY2022Q4	ccel	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	10126574
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	989121
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1463312
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	67867
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	58180
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	44618
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	44618
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	44618
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	729220
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	989121
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	96000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	96000
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	446200
CY2023Q4	us-gaap	Ratio Of Indebtedness To Net Capital1 RatioOfIndebtednessToNetCapital1	3.5
CY2023	ccel	Minimum Debt Service Coverage Ratio MinimumDebtServiceCoverageRatio	1.25
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	8595678
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	8730402
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	165641
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	150527
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	8430037
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	8579875
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	8595678
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	8730402
CY2023	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	140589
CY2022	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	320561
CY2023	us-gaap	Interest Costs Incurred InterestCostsIncurred	824113
CY2023	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	683524
CY2023	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	140589
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	31343695
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	30336749
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8442310
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8792358
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-12304032
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	4024467
CY2023	us-gaap	Interest Expense InterestExpense	1236794
CY2022	us-gaap	Interest Expense InterestExpense	1521767
CY2023Q4	us-gaap	Assets Assets	61220770
CY2022Q4	us-gaap	Assets Assets	64888054
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3078439
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	929618
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	709053
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	229115
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3528119
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1036390
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	954467
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	212258
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3822300
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29129991
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21410674
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8133108
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7807559
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20996883
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13603115
CY2023	us-gaap	Depreciation Depreciation	326000
CY2022	us-gaap	Depreciation Depreciation	333000
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1046000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	566000
CY2023	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	172000
CY2022	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	208000
CY2023	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	683524
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	78964
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	238188
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2061595
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1515680
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1111853
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1038799
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	491920
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	451037
CY2023Q4	ccel	Accrued Income Taxes Benefit Current AccruedIncomeTaxesBenefitCurrent	1426477
CY2022Q4	ccel	Accrued Income Taxes Benefit Current AccruedIncomeTaxesBenefitCurrent	342106
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5170809
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3585810
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1862000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1714000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2908000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2280000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-4945000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1218000
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1806000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-514000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6751000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1732000
CY2023	ccel	Income Tax Expense Benefit Including Current And Deferred IncomeTaxExpenseBenefitIncludingCurrentAndDeferred	-3843000
CY2022	ccel	Income Tax Expense Benefit Including Current And Deferred IncomeTaxExpenseBenefitIncludingCurrentAndDeferred	548000
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	11945000
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	10081000
CY2023Q4	ccel	Deferred Tax Asset From Unconsolidated Affiliate DeferredTaxAssetFromUnconsolidatedAffiliate	1268000
CY2022Q4	ccel	Deferred Tax Asset From Unconsolidated Affiliate DeferredTaxAssetFromUnconsolidatedAffiliate	1252000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	465000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	335000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	3585000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	2524000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	578000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	475000
CY2023Q4	ccel	Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization	3938000
CY2022Q4	ccel	Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization	213000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	20000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	20000
CY2023Q4	ccel	Deferred Tax Assets Tax Revenue Sharing Agreements Buy Out DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut	1097000
CY2022Q4	ccel	Deferred Tax Assets Tax Revenue Sharing Agreements Buy Out DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut	1236000
CY2023Q4	ccel	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	305000
CY2022Q4	ccel	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	171000
CY2023Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	105000
CY2022Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	69000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	268000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	23574000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16376000
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1273000
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	955000
CY2023Q4	ccel	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	292000
CY2022Q4	ccel	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	169000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1565000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1124000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1516000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1510000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	20493000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	13742000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-6000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9000
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2806544
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	696979
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-924411
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0692
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	50556
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0152
CY2023	ccel	Income Tax Reconciliation Increase Decrease In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationIncreaseDecreaseInDeferredTaxAssetsValuationAllowance	-5869
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0004
CY2022	ccel	Income Tax Reconciliation Increase Decrease In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationIncreaseDecreaseInDeferredTaxAssetsValuationAllowance	8865
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0027
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	94115
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.007
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	15313
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0046
CY2023	ccel	Income Tax Reconciliation Permanent Disallowances IncomeTaxReconciliationPermanentDisallowances	50322
CY2023	ccel	Effective Income Tax Rate Reconciliation Permanent Disallowances EffectiveIncomeTaxRateReconciliationPermanentDisallowances	-0.0038
CY2022	ccel	Income Tax Reconciliation Permanent Disallowances IncomeTaxReconciliationPermanentDisallowances	8266
CY2022	ccel	Effective Income Tax Rate Reconciliation Permanent Disallowances EffectiveIncomeTaxRateReconciliationPermanentDisallowances	0.0025
CY2023	ccel	Income Tax Reconciliation Deferred Repricing IncomeTaxReconciliationDeferredRepricing	-98419
CY2023	ccel	Effective Income Tax Rate Reconciliation Deferred Repricing EffectiveIncomeTaxRateReconciliationDeferredRepricing	0.0074
CY2022	ccel	Income Tax Reconciliation Deferred Repricing IncomeTaxReconciliationDeferredRepricing	-126306
CY2022	ccel	Effective Income Tax Rate Reconciliation Deferred Repricing EffectiveIncomeTaxRateReconciliationDeferredRepricing	-0.0381
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	41220
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0032
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-8376
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0024
CY2023	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-204978
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	0.0153
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-80027
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	-0.0241
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3842826
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2875
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	547540
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.165
CY2023	ccel	Minimum Percentage Probability Of Realized Tax Benefit On Settlement MinimumPercentageProbabilityOfRealizedTaxBenefitOnSettlement	0.50
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	1821000
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	1573000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.29
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.53
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	404278
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P4Y5M23D
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	7.36
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	290085
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	7.5
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	95486
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.42
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	123600
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.29
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	104893
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.35
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	0
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	0
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	114193
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.1
CY2004Q2	ccel	Operating Lease Period OperatingLeasePeriod	P10Y
CY2004Q2	ccel	Operating Lease Area Of Facility OperatingLeaseAreaOfFacility	17.600
CY2018Q3	ccel	Extended Operating Lease Area Of Facility ExtendedOperatingLeaseAreaOfFacility	17600
CY2021Q1	ccel	Extended Operating Lease Area Of Facility ExtendedOperatingLeaseAreaOfFacility	17600
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	400716
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	346097
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.15
CY2023	ccel	Defined Contribution Plan Employer Matching Contribution Amount DefinedContributionPlanEmployerMatchingContributionAmount	212000
CY2022	ccel	Defined Contribution Plan Employer Matching Contribution Amount DefinedContributionPlanEmployerMatchingContributionAmount	202000
CY2023	ccel	Payment To Participants Of Profit Sharing Agreement PaymentToParticipantsOfProfitSharingAgreement	1009813
CY2022	ccel	Payment To Participants Of Profit Sharing Agreement PaymentToParticipantsOfProfitSharingAgreement	970037
CY2011Q4	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	1000000
CY2012Q2	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	3000000
CY2015Q2	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	6000000
CY2016Q4	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	8000000
CY2023	us-gaap	Treasury Stock Acquired Repurchase Authorization TreasuryStockAcquiredRepurchaseAuthorization	open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	6562461
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	6347490
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1033157
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	606034
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	225686
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	297691
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	851938
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	313298
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1077624
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	610989
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	306762
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	435970
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	458026
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	38247
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	161381
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1077624
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y29D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y29D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.083
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.035
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	330455
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	342132
CY2023	us-gaap	Impairment Of Ongoing Project ImpairmentOfOngoingProject	13108064
CY2022	us-gaap	Impairment Of Ongoing Project ImpairmentOfOngoingProject	0

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0000950170-24-022275-index-headers.html	Edgar Link	pending
0000950170-24-022275-index.html	Edgar Link	pending
0000950170-24-022275.txt	Edgar Link	pending
0000950170-24-022275-xbrl.zip	Edgar Link	pending
ccel-20231130.htm	Edgar Link	pending
ccel-20231130.xsd	Edgar Link	pending
ccel-ex10_66.htm	Edgar Link	pending
ccel-ex31_1.htm	Edgar Link	pending
ccel-ex31_2.htm	Edgar Link	pending
ccel-ex31_3.htm	Edgar Link	pending
ccel-ex32_1.htm	Edgar Link	pending
ccel-ex97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img16391170_0.jpg	Edgar Link	pending
img264272522_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
ccel-20231130_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CCEL
CRYO CELL INTERNATIONAL INC Stock $ccel

2024 Q1 Form 10-K Financial Statement

#000095017024022275 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CCEL CRYO CELL INTERNATIONAL INC Stock $ccel

2024 Q1 Form 10-K Financial Statement

#000095017024022275 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CCEL
CRYO CELL INTERNATIONAL INC Stock $ccel